>Preliminary Q1 2024 EBITDA of € 522m 16% above cons of € 450m - Positive profit warning (long time not seen) in chemicals with EVK reporting 28% y-o-y growth in prelim EBITDA to € 522m, 16% above cons of € 450m (ODDO BHF € 467m). Includes some € 15m HPPO-licence sales in the SmartMat-segment, but this is not diluting the strong beat. Sales of € 3.8bn declined 5% y-o-y but included some "volume recovery for the first time in two years". Margin recovered to 13.7% in Q1...
As Spring approaches, we see industry-wide destocking coming to an end, emerging recovery trends in China gaining momentum and European spot energy cost relief rolling in, all helping to restore plant utilisation and earnings. We add more cyclicality to our preferred names, upgrading BASF to Outperform (Neutral). Momentum being regained in specialties chemicals distribution triggers our upgrade of IMCD to Outperform (Neutral). ‘From record to record’ remains our mantra at FUCHS. ...
>‘Considerably' better Q1 2024 y-o-y, i.e. +14% on the cards in EBITDA, we think - Management confirmed that volume recovery across most Specialty Additives business units, volume- & price-driven animal nutrition recovery q-o-q, lower energy, logistics and fixed costs support expected 'considerable' adj. EBITDA recovery in Q1 2024. We project 14% y-o-y or € 58m recovery from € 409m in Q1 2023 to € 467m. N&C segment EBITDA may contribute € 70m to the growth. Annual g...
>Q4: Fading group volume decline, positive pricing in animal nutrition - Group sales declined 17% y-o-y to € 3,604m in Q4 2023 (consensus € 3,811m) with still declining but fading group volume headwind by -2% y-o-y (Q3 2023: -5% y-o-y) and pricing effect of -5% y-o-y (Q3 2023: -6%) with positive price trend in animal nutrition mitigating headwinds in Specialty Additives and Smart Materials.Group EBITDA of € 312m -4% vs css of € 325m but digested € 50m exc...
A director at Evonik Industries AG bought 1,705 shares at 17.620EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
>Not getting worse, depressed levels last - We hosted a roadshow with Evonik's CFO, confirming that the market environment is 'at least not getting worse'. However, depressed levels persist with seasonality coming on top at Specialty Additives and Performance Materials, in line with previous communication.Latest proposal on industrial power price - largely no change for Evonik - The recent press release from the ministry of economics, discussing a red...
Since its integration into our European Large Caps Convictions list on 11 January 2023, KPN has made a significant contribution to the list’s performance, thanks to its defensive profile and high dividend yield (11.33% total return). We have decided to take profits as the company is holding its Capital Market Day today. The outlook remains very bright, but the smaller-than-expected share buyback programme announced this morning in the group's press release could disappoint. - ...
Since its integration into our European Large Caps Convictions list on 11 January 2023, KPN has made a significant contribution to the list’s performance, thanks to its defensive profile and high dividend yield (11.33% total return). We have decided to take profits as the company is holding its Capital Market Day today. The outlook remains very bright, but the smaller-than-expected share buyback programme announced this morning in the group's press release could disappoint. - ...
>Group sales declined 21% y-o-y to € 3,771m incl. -5/-6% volume/price y-o-y - Group sales declined 21% y-o-y to € 3,771m in Q3 23 (cons € 3,978m) with a continuation of the decline in group volumes by 5% y-o-y (Q2 23: -9% y-o-y) and a pricing effect of -6% (Q2 23: -5%). Specialty Additives and Smart Materials volumes continued to drop by a double-digit %, mitigated by volume growth in Nutrition & Care.Group EBITDA of € 485m was 6% above consensus of € 456...
Quality has been the best performing investment style since the Fed held its last meeting and interest rates rose amid whilst at the same time concerns regarding the cycle in Europe have heightened. Within the Stoxx 600, we have selected the 25 stocks in our coverage universe that best match this Quality style, with an Outperform recommendation and upside potential of more than 20% relative to our equity analysts’ target prices. - ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.